The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of rare autoimmune disorder Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS. The only other treatment approved for LEMS is only approved for use in adults.
LEMS affects the connection between nerves and muscles, disrupting the ability of nerve cells to send signals to muscle cells.
The treatment currently available has been approved only for adults.
Read the FDA news release